Drug Target Review

JANUARY 23, 2024

In April 2023, we saw the first randomised data applying an individualised vaccine in combination with checkpoint inhibition for resectable melanoma, demonstrating benefit in terms of time to disease recurrence. Espen integrates clinical and research expertise as Director of Medical Affairs.

Treatment 122

Treatment Immune Response Vaccine Therapies 122

Drug Discovery World

MAY 30, 2024

As we age, in adult life, changes in immunity, in particular in immune cells, affect how we respond to vaccines. This change in our ability to respond to vaccines also makes us vulnerable to infectious disease. RA: Why have you selected lymph nodes as the target for vaccine responses in this study?

Vaccine 147

Vaccine Protein Expression Immune Response Clinical Trials 147

Drug Discovery World

JULY 29, 2022

From immunity to metabolism to mental health, it seems like the gut microbiome has been linked to every aspect of human health and disease. The usual suspects for triggering an immune response would be a protein or a sugar,” said Clardy. muciniphila’s ability to manipulate the immune system and fight disease.

Research 130

Research Immune Response Medical Schools Disease 130

The Pharma Data

DECEMBER 29, 2020

29, 2020 /PRNewswire/ — Phase 3 program in hospitalized patients to continue based on passing futility analysis on ability to reduce incidence of death or mechanical ventilation. As in earlier outpatient trial, immune status when patients entered the trial was a strong predictor of viral load and clinical outcomes.

Hospitals 52

Hospitals Trials Clinical Trials Production 52

Drug Target Review

DECEMBER 28, 2023

These neoantigens are identified by T cells of the immune system as foreign proteins and thus trigger an immune response. Neoantigens are recognised as non-self and trigger an immune response. Patients with high numbers of clonal neoantigens show improved disease-free survival.

Bioinformatics 105

Bioinformatics Immune Response DNA Vaccine 105

The Pharma Data

MARCH 8, 2022

Gunther Hartmann from the Institute of Clinical Chemistry and Clinical Pharmacology at the University Hospital Bonn, in cooperation with other members of the cluster of excellence ImmunoSensation2 at the University of Bonn, have shown this in mice. Also, the incidence of severe disease progression was observed to be significantly reduced.

Clinical Pharmacology 52

Clinical Pharmacology Immune Response RNA Virus 52

The Pharma Data

DECEMBER 17, 2020

(NASDAQ: REGN ) today announced that the New England Journal of Medicine (NEJM) has published initial clinical data from an ongoing seamless Phase 1/2/3 trial of the antibody cocktail casirivimab and imdevimab in non-hospitalized patients with COVID-19. “The investigational cocktail is now available to indicated high-risk U.S.

Hospitals 52

Hospitals Production Clinical Trials Virus 52

Drug Discovery World

OCTOBER 21, 2022

While advances in treatment over the last few years have resulted in good overall survival rates for patients with non-metastatic disease (90% five-year survival rate in the US 1 ), outcomes are still poor in certain cancers that do not respond to standard therapies. 3D bioprinted breast cancer tumours.

Therapies 130

Therapies Small Molecule Immune Response Engineering 130

The Pharma Data

APRIL 8, 2022

Now, new research from the Wyss Institute at Harvard University has revealed that this constant pattern of stretching and relaxing does even more – it generates immune responses against invading viruses. a Wyss Technology Development Fellow at the Institute. ” The results are published today in Nature Communications. .

Virus 52

Virus Immune Response Disease Clinical Trials 52

Broad Institute

JULY 26, 2022

Researchers decipher how a gut bacterium influences immunity By Corie Lok July 26, 2022 Breadcrumb Home News Researchers decipher how a gut bacterium influences immunity Study finds a molecule made by the bacterium that helps moderate immune responses. It gets its name from the intestinal mucus it breaks down.

Research 52

Research Immune Response Medical Schools Disease 52

The Pharma Data

JANUARY 22, 2021

Regeneron’s monoclonal antibody cocktail reduced medical visits for COVID-19 patients who had not been hospitalized by almost 50 percent, according to interim clinical trial results reported by researchers at the company. The EUA covers adults and children over age 12 who have mild or moderate COVID-19 and are at high risk for severe disease.

Immune Response 52

Immune Response Hospitals Clinical Trials Trials 52

NIH Director's Blog: Drug Development

JUNE 30, 2020

It’s now clear that nearly everyone who recovers from coronavirus disease 2019 (COVID-19) produces antibodies that specifically target SARS-CoV-2, the novel coronavirus that causes the infection. But there is a catch: 99 percent of the study’s participants didn’t make enough neutralizing antibodies to mount an ideal immune response.

Immune Response 52

Immune Response Virus Vaccine Research 52

Drug Discovery World

MAY 6, 2024

The company is now investigating a promising gene therapy for Huntingdon’s disease in a Phase I/II trial, with patients already showing signs of preserved neurological function. In Paris itself, Institut Curie is a major cancer hospital, from which One Biosciences was spun-off.

Drugs 147

Drugs Science Molecular Biology Clinical Trials 147

The Pharma Data

SEPTEMBER 14, 2020

A new antibody treatment is to be trialled on Covid-19 patients in UK hospitals. This is then given to patients, immediately boosting their immune response. The UK Recovery Trial was set up at the start of the pandemic to identify treatments that could help people admitted to hospital with Covid-19. Image copyright.

Trials 52

Trials Immune Response Virus Vaccine 52

The Pharma Data

AUGUST 24, 2020

Those infected develop an immune response as their bodies fight off the virus which helps to protect them against it returning. The strongest immune response has been found in the most seriously ill patients. But it is still not clear how strong this protection or immunity is – or how long it lasts.

Virus 52

Virus Immune Response Hospitals Vaccine 52

The Pharma Data

OCTOBER 23, 2020

A solidarity clinical trial “is one of the largest international randomized trials for Covid-19 treatments, enrolling almost 12,000 patients in 500 hospital sites in over 30 countries”, according to the World Health Organization (WHO), which launched the trail with a number of partners. Overall, in-hospital mortality was 12.9

Trials 52

Trials Immune Response Hospitals Clinical Trials 52

Drug Discovery World

APRIL 20, 2023

SARS-CoV-2 particles spread through the respiratory mucosa and other infected cells, causing changes in peripheral immune cells and eliciting a cascade of immune responses, resulting in a detrimental cytokine storm. Alzheimer’s disease), or by initiating a new one. depression). F Ceban et al., Academic Press Inc.,

Drug Development 246

Drug Development Clinical Trials Drugs Virus 246

The Pharma Data

APRIL 22, 2023

Multiple sclerosis (MS) is a devastating autoimmune disease that destroys the protective myelin covering around nerves, disrupting communication between the brain and body, and causing patients’ ability to move and function to progressively decline. million individuals that currently have to live with the disease.

Therapies 40

Therapies Immune Response Small Molecule Engineering 40

Broad Institute

JUNE 14, 2023

She is also a member of the board of trustees of the Massachusetts Health & Hospital Association. A trailblazer in cancer research, Glimcher's research identified key transcriptional regulators of protective immunity and the origin of pathophysiologic immune responses underlying autoimmune, infectious, and malignant diseases.

Medical Schools 52

Medical Schools Immune Response Science Hospitals 52

The Pharma Data

AUGUST 9, 2021

The pre-clinical animal trials of the intranasal vaccine showed a reduction in both the impact of the disease itself and transmission of the virus. This should prevent both clinical disease and virus transmission, to halt the spread of the COVID-19 pandemic.

Vaccine 52

Vaccine Virus Immune Response Disease 52

The Pharma Data

JUNE 1, 2022

Blocking an immune response-related enzyme holds promise in preventing or treating severe COVID-19 symptoms by reducing inflammation, tissue injury and blood clots in the lungs, new research in mice suggests. Previous research has shown that caspase 11 in mice has many of the same immune-response functions as caspase 4 in humans.

Immune Response 52

Immune Response Virus Engineering Disease 52

The Pharma Data

DECEMBER 9, 2020

In the new study, researchers found that among COVID patients at their safety-net hospital, neurological complications ran the gamut. Safety-net hospitals are obligated, by mandate or mission, to treat people regardless of their ability to pay. Aaron Glatt, a spokesperson for the Infectious Diseases Society of America.

Hospitals 52

Hospitals Doctors Immune Response Nurses 52

The Pharma Data

NOVEMBER 10, 2020

P otential to be a safer and effective alternative to the intravenous immunotherapies currently used for Crohn’s Disease. Crohn’s Disease Therapeutics Market Size $4.7 Oral and nasal administration routes are both physiologic approaches to stimulate the mucosal immune system to induce disease modifying benefits.”.

Clinical Trials 40

Clinical Trials Science Disease Trials 40

The Pharma Data

JUNE 17, 2022

In a Phase 2/3 clinical trial, the Pfizer-BioNTech COVID-19 Vaccine elicited a strong immune response in this age group Three 3-µg doses had favorable safety profile similar to placebo in young children ages 6 months through 4 years in Phase 2/3 clinical trial Pfizer-BioNTech COVID-19 Vaccine now authorized in the U.S. About BioNTech.

Vaccine 52

Vaccine FDA Clinical Trials Immune Response 52

The Pharma Data

SEPTEMBER 6, 2021

Based on current evidence, there is no urgent need for the administration of booster doses of vaccines to fully vaccinated individuals in the general population, according to a technical report issued by the European Centre for Disease Prevention and Control (ECDC). Source link : [link].

Long-Term Care Facilities 52

Long-Term Care Facilities Vaccine Immune Response Virus 52

Broad Institute

DECEMBER 6, 2023

The immune system can carry out many biological processes, from killing viruses to fighting cancer, thanks in large part to approximately 100 key cell-signaling proteins called cytokines, which instruct immune cells what to do. The reference, called the Immune Dictionary , appears today in Nature.

Immune Response 138

Immune Response RNA Medical Schools Disease 138

The Pharma Data

OCTOBER 19, 2020

Immune responses following vaccination with PNEUMOVAX 23 (month 13) were comparable in both vaccination groups for the 15 serotypes in V114. Results from both studies are based on opsonophagocytic activity (OPA) responses – a measure of vaccine-induced functional antibodies. among adults 65 years of age or older.

Vaccine 52

Vaccine Immune Response Disease Clinical Trials 52

The Pharma Data

AUGUST 16, 2021

Vaccination is our most effective means of preventing COVID-19 infection – especially severe disease and hospitalization – and its profound impact on protecting lives is indisputable. today announced that they have submitted Phase 1 data to the U.S. today announced that they have submitted Phase 1 data to the U.S.

Vaccine 52

Vaccine FDA Virus Immune Response 52

Drug Target Review

FEBRUARY 21, 2024

Stem cell transplants primarily help the immune response through the “graft-versus-leukaemia effect,” and we have to manage the “graft versus host effect.” To this end, last August we opened our Cancer Center at Lehigh Valley Hospital–Hazleton campus. Dr Nair received his medical degree from Jefferson Medical College.

Therapies 64

Therapies Treatment Vaccine FDA Approval 64

The Pharma Data

NOVEMBER 18, 2020

.” Ming-Tain Lai, PhD, Chief Scientific Officer at OBI Pharma stated, “In the trial, OBI-833 demonstrated a favorable safety profile and generated detectable anti-Globo H IgM/IgG responses. Department of Internal Medicine, Tri-Service General Hospital, Taipei, Taiwan. ” Presentation number: 397P / Poster: ID 680.

Vaccine 52

Vaccine Small Molecule Immune Response Hospitals 52

The Pharma Data

DECEMBER 8, 2020

In August, the company reported the vaccine candidate triggered antibody-based immune responses in early and mid-stage trials. Sinopharm’s vaccine was developed from a SARS-CoV-2 strain isolated from a patient in the Jinyintan Hospital, Wuhan. The vaccine was also demonstrating a strong safety profile.

Vaccine 52

Vaccine Immune Response Virus Clinical Trials 52

The Pharma Data

FEBRUARY 23, 2022

. * In the VAT08 Phase 3 primary series trial, two doses of the Sanofi-GSK vaccine in seronegative populations demonstrated: * 100% efficacy against severe COVID-19 disease and hospitalizations * 75% efficacy against moderate or severe COVID-19 disease * 57.9%

Vaccine 52

Vaccine Virus Trials Immune Response 52

The Pharma Data

DECEMBER 16, 2020

Instead, it uses a genetic code, which tricks the body into developing an immune response to the virus. This positive primary analysis confirms the ability of our vaccine to prevent COVID-19 disease with 94.1% The technology leveraged to create the vaccine does not require the actual virus, according to CNN.

Vaccine 52

Vaccine Immune Response FDA FDA Approval 52

The Pharma Data

JANUARY 17, 2021

The primary endpoint of the study was composite of time to first occurrence of heart failure hospitalization or cardiovascular death. By inhibiting calcineurin, the drug blocks IL-2 expression and T-cell mediated immune responses. The NDA was built on data from the Phase III VICTORIA trial.

FDA 52

FDA Small Molecule Immune Response Hospitals 52

The Pharma Data

JANUARY 10, 2021

Evidence continues to build for long-lasting immunity to COVID-19 following disease infection, with the publication of a new study showing a durable immune response as far as eight months after the initial onset of symptoms.

Immune Response 52

Immune Response Vaccine Hospitals Research 52

The Pharma Data

JANUARY 11, 2021

“Because COVID-19 is such a new disease, we are only beginning to understand some of its long-term effects on patients’ health,” said researcher Dr. Bin Cao, from the National Center for Respiratory Medicine at the China-Japan Friendship Hospital and Capital Medical University, both in Beijing.

Hospitals 52

Hospitals Virus Vaccine Immune Response 52

The Pharma Data

NOVEMBER 12, 2020

The CALAVI trials were launched based on preclinical and early clinical evidence that Calquence could decrease the hyperinflammatory immune response and improve clinical outcomes in patients hospitalised with respiratory symptoms of COVID-19.1 The data will be presented in due course. CALAVI US). NCT identifier: NCT04380688.

Trials 52

Trials Clinical Trials Immune Response FDA Approval 52